Delving into the Latest Updates on NovoTek Therapeutics, Inc. with Synapse

Overview

Tags

Immune System Diseases

Respiratory Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

Top II(Topoisomerase II)	1

主要目的：确定注射用盐酸莎巴比星治疗小细胞肺癌（广泛期）患者的最大耐受剂量及剂量限制性毒性，评价注射用盐酸莎巴比星治疗小细胞肺癌（广泛期）患者体内药代动力学特征。次要目的：初步评价注射用盐酸莎巴比星治疗小细胞肺癌（广泛期）的有效性与安全性，为Ⅱ期临床研究推荐合理用药方案。

[Translation]

The primary objective is to determine the maximum tolerated dose and dose-limiting toxicity of sabalibixin hydrochloride injection in the treatment of patients with small cell lung cancer (extensive stage), and to evaluate the pharmacokinetic characteristics of sabalibixin hydrochloride injection in the treatment of patients with small cell lung cancer (extensive stage). The secondary objective is to preliminarily evaluate the efficacy and safety of sabalibixin hydrochloride injection in the treatment of small cell lung cancer (extensive stage), and to recommend a reasonable medication regimen for Phase II clinical studies.

Start Date-

Sponsor / Collaborator

NovoTek Therapeutics, Inc.

[+1]

CTR20150203 / RecruitingPhase 1

注射用盐酸莎巴比星联合顺铂治疗小细胞肺癌（广泛期）安全性、耐受性及药代动力学Ⅰ期临床研究

[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of sabalibixin hydrochloride for injection combined with cisplatin in the treatment of small cell lung cancer (extensive stage)

主要目的：确定注射用盐酸莎巴比星联合顺铂治疗小细胞肺癌（广泛期）患者的最大耐受剂量及剂量限制性毒性，评价注射用盐酸莎巴比星治疗小细胞肺癌患者体内药代动力学特征。次要目的：初步评价注射用盐酸莎巴比星联合顺铂治疗小细胞肺癌（广泛期）的有效性与安全性，为Ⅱ期临床研究推荐合理给药方法。

[Translation]

Primary objective: To determine the maximum tolerated dose and dose-limiting toxicity of sabalibixin hydrochloride for injection combined with cisplatin in the treatment of patients with small cell lung cancer (extensive stage), and to evaluate the pharmacokinetic characteristics of sabalibixin hydrochloride for injection in the treatment of patients with small cell lung cancer. Secondary objective: To preliminarily evaluate the efficacy and safety of sabalibixin hydrochloride for injection combined with cisplatin in the treatment of small cell lung cancer (extensive stage), and to recommend a reasonable dosing method for phase II clinical studies.

Start Date28 Aug 2014

Sponsor / Collaborator

NovoTek Therapeutics, Inc.

[+1]

100 Clinical Results associated with NovoTek Therapeutics, Inc.

Login to view more data

0 Patents (Medical) associated with NovoTek Therapeutics, Inc.

Login to view more data

100 Deals associated with NovoTek Therapeutics, Inc.

Login to view more data

100 Translational Medicine associated with NovoTek Therapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BDDE cross-linked sodium hyaluronate gel	Osteoarthritis, Knee More	Approved
Sabarubicin Hydrochloride ( Top II )	Refractory Lung Small Cell Carcinoma More	Phase 1